Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600129001) titled 'Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II' on July 29.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Tianjin Medical University Cancer Institute and Hospital
Condition:
Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-08-01
Target Sample Size: Treatment Group:36;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=333727
Published by HT Digital Content Services with p...